Advancing Regenerative Medicine Manufacturing Solutions: Paving the Way for New Regenerative Medicine Products
Published on May 13, 2025
ReMDO, in partnership with MTEC, is advancing regenerative medicine manufacturing through industry-driven programs. Key efforts include developing universal cell media and tunable bioinks for 3D bioprinting. These innovations aim to standardize processes and support the production of next-generation therapies for both military and civilian healthcare applications.
Research Highlight
The RegenMed Development Organization (ReMDO) leads an industry-driven consortium focused on advancing regenerative medicine manufacturing technologies in the precompetitive space. ReMDO currently manages two key MTEC-funded programs: one to develop a universal media for clinical cell manufacturing, and another to create a tunable bioink to support 3D bioprinting and biomanufacturing. Both programs are built on strong industry collaboration to accelerate platform technology innovation.
Recent milestones from the ReMDO Bioink Program include the development of specialized bioink formulations for targeted tissue types, supplements for difficult-to-culture cells, and engineered base bioinks optimized for 3D printing and additive manufacturing. The team is now applying these technologies across multiple printer platforms and standardizing procedures for bioengineering applications.
ReMDO is proud to collaborate with MTEC in advancing regenerative medicine solutions that benefit both wounded warriors and civilian patients by supporting the commercialization of next-generation therapies.